What is the difference between compounded and branded GLP-1 medication?
Branded GLP-1 medications
Branded GLP-1 medications — such as Wegovy, Ozempic, Mounjaro, and Zepbound — have completed the new drug approval process conducted by the U.S. Food and Drug Administration. That process includes clinical trials submitted for review of safety and effectiveness, manufacturing inspections, and ongoing post-market surveillance requirements.
Compounded GLP-1 medications
Compounded GLP-1 medications are prepared by licensed compounding pharmacies. They are not the same product as any branded GLP-1 medication, even when the active pharmaceutical ingredient is the same compound. The compounding process, formulation, and quality-oversight framework differ from those of products that have completed the new drug approval process.
What differs in practice
- Regulatory pathway: Branded = completed new drug approval. Compounded = pharmacy license under state and federal compounding law.
- Formulation: Branded medications have a standardized, reviewed formulation. Compounded medications may vary in formulation, concentration, or added ingredients by pharmacy.
- Cost: Branded medications covered by insurance may have lower net cost for some patients. Cash-pay compounded medications are often less expensive than branded medications without insurance coverage.
- Availability: Branded medications are subject to manufacturer production and insurance formulary decisions. Compounded availability is subject to individual pharmacy capacity and regulatory conditions.
Neither option is right for every patient. Independent licensed providers evaluate each patient individually and recommend what is medically appropriate for that individual. No specific medication option is promised or assured through any program.
Availability varies by state. Confirm what is available in your state at the time of your evaluation.